Evidence map›Paper›PMID 37821650›Full record

ArticleCommunications biology2023

MUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression.

Atrayee Bhattacharya, Atsushi Fushimi, Keyi Wang, Nami Yamashita, Yoshihiro Morimoto, Satoshi Ishikawa, Tatsuaki Daimon, Tao Liu, Song Liu, Mark D Long and 1 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Research progress of MUC1 in genitourinary cancers.Cellular & molecular biology letters · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Atrayee BhattacharyaDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Atsushi FushimiDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Keyi WangDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nami YamashitaDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Yoshihiro MorimotoDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Satoshi IshikawaDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Tatsuaki DaimonDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Tao LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-8818-8313
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Mark D LongDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0003-1120-8176
Donald KufeDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Donald_Kufe@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-5743-8888
Harvard University · USRoswell Park Comprehensive Cancer Center · US

Funding

Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCIU24CA232979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HUTSON, ALAN DAVID, LIU, SONG · 2018 to 2024
$8.9M
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast CancerR01CA097098 · NCI · DANA-FARBER CANCER INSTITUTE · PI DONALD W. KUFE · 2002 to 2026
$8.8M
MUC1-C is a Target for Reversing Immune Evasion and Resistance to ImmunotherapiesU01CA233084 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2018 to 2022
$4.1M
Acquisition of High Performance Data and Computing Infrastructure to Advance Biomedical ResearchS10OD024973 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI FURLANI, THOMAS · 2019 to 2019
$1.0M
Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancerR21CA262991 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W. · 2022 to 2022
$442k
NCI NIH HHS R01 CA097098NCI NIH HHS R21 CA262991NCI NIH HHS U01 CA233084NCI NIH HHS U24 CA232979NIH HHS S10 OD024973
6 · The paper itself

Abstract

Chronic inflammation promotes epigenetic reprogramming in cancer progression by pathways that remain unclear. The oncogenic MUC1-C protein is activated by the inflammatory NF-κB pathway in cancer cells. There is no known involvement of MUC1-C in regulation of the COMPASS family of H3K4 methyltransferases. We find that MUC1-C regulates (i) bulk H3K4 methylation levels, and (ii) the COMPASS SET1A/SETD1A and WDR5 genes by an NF-κB-mediated mechanism. The importance of MUC1-C in regulating the SET1A COMPASS complex is supported by the demonstration that MUC1-C and WDR5 drive expression of FOS, ATF3 and other AP-1 family members. In a feedforward loop, MUC1-C, WDR5 and AP-1 contribute to activation of genes encoding TRAF1, RELB and other effectors in the chronic NF-κB inflammatory response. We also show that MUC1-C, NF-κB, WDR5 and AP-1 are necessary for expression of the (i) KLF4 master regulator of the pluripotency network and (ii) NOTCH1 effector of stemness. In this way, MUC1-C/NF-κB complexes recruit SET1A/WDR5 and AP-1 to enhancer-like signatures in the KLF4 and NOTCH1 genes with increases in H3K4me3 levels, chromatin accessibility and transcription. These findings indicate that MUC1-C regulates the SET1A COMPASS complex and the induction of genes that integrate NF-κB-mediated chronic inflammation with cancer progression.

Indexed as

NeoplasmsNF-kappa BEpigenesis, GeneticHumansInflammationIntracellular Signaling Peptides and ProteinsMucin-1Neoplastic ProcessesTranscription Factor AP-1Intracellular Signaling Peptides and ProteinsMUC1 protein, humanMucin-1NF-kappa BTranscription Factor AP-1WDR5 protein, human

Identifiers

PMID37821650
PMCPMC10567710
OpenAlexW4387526679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.